Fig. 5

Cross-talk analysis of individual antagonists against EGF, NRG1b, and c-Met illustrates receptor signaling co-involvement. Percent inhibitions of abnormal signaling are listed for paired antagonists (Tables 5, 6, 7) . The data in Fig. 5 demonstrates for three different HER2 negative patients where treatment with the antagonist drug indicated at the column head affects the signaling generated by the agonist indicated at the matching row for each patient. For ‘on target’ pairing of drug and agonist for each patient shown, the data for duplicate wells demonstrate > 85% efficacy at reducing the abnormal signaling (indicated in bold font) directly related to the target binding receptor indicated in column headings. When considering ‘off target’ effects for patient C1061 for example, Tepotinib treatment leads to a 98% increase in signaling (negative value for inhibition, in red font) upon NRG addition and 40% increase for EGF addition. For C1061 and patient C753, treatment with a HER2 specific antagonist leads to an increase in HGF signaling